SCHEMBL21393426

SCHEMBL21393426

CCC(=O)c1cccc(CBr)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.41
BRD4 O60885 1/20 0.41
NPSR1 Q6W5P4 2/20 0.37
KDM4E B2RXH2 2/20 0.36
ALOX15 P16050 2/20 0.36
TSHR P16473 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
ACMSD Q8TDX5 1/20 0.36
CCR1 P32246 1/20 0.35
KCNH2 Q12809 1/20 0.35
P2RX7 Q99572 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MRGPRX4 Q96LA9 2/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
OPRK1 P41145 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25139435 0.84 CYP1A2 (0.42) CYP1A2BRD4NPSR1KDM4EALOX15
SCHEMBL1596880 0.82 CYP1A2 (0.55) CYP1A2NPSR1KDM4EALOX15TSHR
SCHEMBL30401197 0.81 NPSR1 (0.43) CYP1A2BRD4NPSR1KDM4EALOX15
SCHEMBL4859332 0.81 NPSR1 (0.43) CYP1A2BRD4NPSR1KDM4EALOX15
SCHEMBL9360084 0.81 KDM4E (0.41) CYP1A2BRD4NPSR1KDM4EALOX15
SCHEMBL2348706 0.79 KDM4E (0.61) BRD4KDM4EALOX15TSHRTDP1
SCHEMBL2108801 0.78 CYP1A2 (0.72) CYP1A2NPSR1KDM4ETSHRSMN1; SMN2
SCHEMBL6564811 0.78 ALDH1A1 (0.49) CYP1A2KDM4EALOX15TSHRTDP1
SCHEMBL28849815 0.78 PIM1 (0.43) CYP1A2BRD4NPSR1KDM4EALOX15
SCHEMBL1181244 0.77 MAPT (0.51) CYP1A2BRD4SMN1; SMN2MRGPRX4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019182938-A1 AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE VIRGINIA COMMONWEALTH UNIVERSITY (US) 2019-09-26 WO disclosed